Pliant Therapeutics to Present at European Liver Congress

SOUTH SAN FRANCISCO, Calif., May 07, 2024 - Pliant Therapeutics, Inc. (Nasdaq: PLRX), a prominent biotechnology company specializing in the development of innovative treatments for fibrotic diseases, has announced its participation in the European Association for the Study of the Liver (EASL) International Liver Congress™. This event is scheduled to take place in Milan, Italy, from June 5-8, 2024. Pliant Therapeutics is set to present two significant posters, one of which is a late-breaking presentation.

The first poster presentation is titled "Oral alpha-v/beta-6 and alpha-v/beta-1 integrin inhibitor bexotegrast in primary sclerosing cholangitis: Updated 12-week interim safety and efficacy analysis of the INTEGRIS-PSC Phase 2a trial." This late-breaking abstract, numbered LB27, will be presented by Michael Trauner, M.D., who serves as the Chair of Gastroenterology and Hepatology at the Department of Medicine III, Medical University Clinic, Vienna, Austria. The presentation is scheduled to be displayed from Wednesday, June 5, 2024, at 8:30 a.m. to Saturday, June 8, 2024, at 5:00 p.m. CEST.

The second poster presentation is titled "Dual alpha-v/beta-6 and alpha-v/beta-1 integrin inhibitor bexotegrast targets TGF-beta inhibition to specific cell types in human liver explant tissue with biliary fibrosis." This abstract, numbered 1627, will be presented by Johanna Schaub, Ph.D., Principal Scientist II in Translational Sciences at Pliant Therapeutics. The presentation will be available on Thursday, June 6, 2024, from 8:30 a.m. to 6:00 p.m. CEST.

Pliant Therapeutics, Inc. is recognized as a leader in the late-stage biopharmaceutical industry, primarily focusing on the discovery and development of novel therapies for fibrotic diseases. The company's leading product candidate, bexotegrast (PLN-74809), is an oral, small molecule, dual selective inhibitor of αvß6 and αvß1 integrins. It is being developed for the treatment of idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC). Bexotegrast has earned Fast Track Designation and Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for both IPF and PSC. Additionally, it has received Orphan Drug Designation from the European Medicines Agency for these conditions.

Pliant Therapeutics has launched the BEACON-IPF trial, a Phase 2b/3 study of bexotegrast in IPF. The company is also conducting a Phase 1 study for its third clinical program, PLN-101095. This program involves a small molecule, dual-selective inhibitor of αvß8 and αvß1 integrins, which is being developed to treat solid tumors. Furthermore, Pliant Therapeutics has received regulatory approval to conduct a Phase 1 study of PLN-101325, a monoclonal antibody against integrin α7β1, aimed at addressing muscular dystrophies. 

Pliant Therapeutics continues to advance its pipeline of novel therapeutics, aiming to address significant unmet medical needs in the field of fibrotic diseases. The company's participation in the upcoming EASL International Liver Congress™ underscores its commitment to sharing groundbreaking research and fostering collaboration within the scientific community.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!